In Brief: A New Indication for Uzedy
Abstract
Uzedy, an extended-release, subcutaneous (SC) formulation of the second-generation antipsychotic drug risperidone, was approved by the FDA in 2023 for treatment of schizophrenia in adults. It has now been approved for use as monotherapy or in combination with lithium or valproate for maintenance treatment of bipolar I disorder in adults. Extended-release, intramuscular (IM) formulations of risperidone (Risperdal Consta and Rykindo) are also approved for treatment of bipolar I disorder (see Table 1).
Fields of Study & Subjects
Bipolar Disorder and Treatment
Phosphodiesterase function and regulation
Chemical Reactions and Isotopes
Publication details
- Journal / source
- The medical letter on drugs and therapeutics/The medical letter
- Volume
- 68
- Issue
- 1746
- Pages
- 15–16
- Publication date
- 19 January 2026
- Language
- EN